IRulya Therapeutics Inc. Common Stock
IRLA
37 hedge funds and large institutions have $12.5M invested in IRulya Therapeutics Inc. Common Stock in 2025 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 6 increasing their positions, 9 reducing their positions, and 4 closing their positions.
125% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 4
80% more capital invested
Capital invested by funds: $6.96M → $12.5M (+$5.55M)
16% more funds holding
Funds holding: 32 → 37 (+5)
4.78% more ownership
Funds ownership: 11.89% → 16.67% (+4.8%)
33% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$2.89M |
| 2 |
Rockefeller Capital Management
New York
|
+$194K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$192K |
| 4 |
USPCM
Union Square Park Capital Management
New York
|
+$138K |
| 5 |
Millennium Management
New York
|
+$126K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
IEQ Capital
Foster City,
California
|
-$420K |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$245K |
| 3 |
Renaissance Technologies
New York
|
-$137K |
| 4 |
VF
Virtu Financial
New York
|
-$58K |
| 5 |
Morgan Stanley
New York
|
-$56.2K |
IRLA Hedge Fund Activity: Q2 2025 in Review
37 of the 7,617 institutional investors tracked by Wall St. Rank reported a position in IRulya Therapeutics Inc. Common Stock (IRLA) for Q2 2025, worth a combined $12.5M — up 80% from $6.96M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new IRLA positions and 4 closed out — a net gain of 5 holders — while 6 added to existing stakes and 9 trimmed.
The largest buyer was Nantahala Capital Management, opening a new position worth an estimated $2.89M. The largest seller was IEQ Capital, cutting an estimated $420K.
- 37 institutional investors held IRulya Therapeutics Inc. Common Stock (IRLA) as of Q2 2025, up from 32 in Q1 2025.
- Funds reported $12.5M of IRulya Therapeutics Inc. Common Stock stock for Q2 2025, up 80% quarter-over-quarter.
- 9 funds opened new IRulya Therapeutics Inc. Common Stock positions in Q2 2025 and 4 closed out, a net change of +5 holders.
- The largest IRulya Therapeutics Inc. Common Stock buyer in Q2 2025 was Nantahala Capital Management, an estimated $2.89M added.
- The largest IRulya Therapeutics Inc. Common Stock seller in Q2 2025 was IEQ Capital, an estimated $420K sold.
Based on aggregated 13F filings for Q2 2025.